Federal contract award
75A50123C00055
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT, INCLUDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL, OF ATROPINE AUTOINJECTOR FOR PEDIATRIC USE USING AN IMPROVED VERSION OF RAFA LABORATORIES, LTD.S (RAFAS) FDA-APPROVED SI
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | BARDA - ASPR / DAAPPO / BARDA DCMA |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $9.4M |
| Current contract value | $9.4M |
| Potential contract value / ceiling | $14.7M |
| Start date | Sep 19, 2023 |
| Current end date | Aug 4, 2028 |
| Potential end date | Jan 1, 2030 |
| Latest award activity | Sep 22, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 22, 2025 | P00002 | $1.7M | SUPPLEMENTAL FUNDING FOR CLIN 001, REVISE STATEMENT OF WORK, ADD ALT COR, AND ADD ATTACHMENT 7 EO FAR CLAUSE CHANGES. |
| Aug 14, 2024 | P00001 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO UPDATE SECTION E.1 INSPECTION AND ACCEPTANCE, SECTION F.3.2.E OTHER REQUIREMENTS/DELIVERABLES, SECTION G.1 CONTRACTING OFFICER, AND ARTICLE G.4. KEY PERSONNEL AT NO COST TO THE GOVERNMENT. |
| Sep 19, 2023 | 0 | $7.7M | THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT, INCLUDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL, OF ATROPINE AUTOINJECTOR FOR PEDIATRIC USE USING AN IMPROVED VERSION OF RAFA LABORATORIES, LTD.S (RAFAS) FDA-APPROVED SI |
Estimated positioning window
Jan 1, 2029 – Jul 1, 2029
30/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 30/100. Available recorded signals: 25 points.
- Contract end 2030-01-01 (1164 days from calculation)
- +5 points
- 121 historical awards in this buyer and category group
- +15 points
- 3 recorded award transactions
- +5 points
- Latest award action: 2025-09-22
- +0 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +0 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.